Protein C human 500unit powder and solvent for solution for injection vials
Requires a prescription from a doctor or prescriber
Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Protein C human on the MHRA register
Ceprotin 500unit powder and solvent for solution for injection vials
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(13)
Chronic kidney disease: assessment and management (NG203)
Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32)
QuikRead go for C-reactive protein testing in primary care (MIB78)
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Spondyloarthritis in over 16s: diagnosis and management (NG65)
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues (HTG535)
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
The NGAL Test for early diagnosis of acute kidney injury (MIB3)
Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
Type 1 diabetes in adults: diagnosis and management (NG17)
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Reviews & meta-analyses: 2 · 1979–2017
Showing all 30 studies, sorted by most relevant.
J. Griffin, B. Zlokovic, L. Mosnier
Blood, 2015
- Cytoprotection
- Anticoagulants
- Protein C
G. R. Bernard, J. L. Vincent, P. Laterre, et al.
The New England journal of medicine, 2001
- Anti-Inflammatory Agents, Non-Steroidal
- Fibrin Fibrinogen Degradation Products
- Fibrinolytic Agents
Jeffrey S Barkun, N. V. Christou
2003
Tong-fei Cheng, Dong Liu, J. Griffin, et al.
Nature Medicine, 2003
- Antibodies
- Blood Coagulation Factors
- Brain
D. Eaton, H. Rodriguez, G. Vehar
Biochemistry, 1986
W. Kisiel
Journal of Clinical Investigation, 1979
- Blood Coagulation
- Chemistry
- Enzyme Activation
D. Foster, S. Yoshitake, E. Davie
Proceedings of the National Academy of Sciences of the United States of America, 1985
- Genes
- Amino Acid Sequence
- Base Sequence
K. Suzuki, J. Stenflo, B. Dahlbäck, et al.
The Journal of biological chemistry, 1983
- Amino Acids
- Blood Coagulation Factors
- Enzyme Activation
Thrombin-activated vitamin K-dependent protein C purified from human plasma has a potent anticoagulant effect on human plasma, whereas its bovine counterpart has a very weak anticoagulant effect on human plasma. This species difference was found to be partly due to a more rapid degradation of human factor Va by human than by bovine activated protein C. In the presence of phospholipid, activated human protein C cleaves several peptide bonds in fragment D (heavy chain of factor Va), whereas in fragment F1F2 (light chain of factor Va) there appears to be only one peptide bond that is slowly cleaved. The degradation of fragment D is accompanied by a parallel loss of factor V activity. With the blood coagulation factor Xa bound to factor Va, fragment D is protected from degradation by activated protein C, and factor Va remains active. Fragment D isolated from factor Va was exposed to activated protein C in the presence of phospholipid and was found not to be degraded. This observation suggests that fragment D of factor V is bound to phospholipid via fragment F1F2.
Abstract licence: CC BY
C. Fulcher, J. E. Gardiner, J. Griffin, et al.
Blood, 1984
- Antigens
- Electrophoresis, Polyacrylamide Gel
- Factor VIII
C. Willcox, V. Pitard, S. Netzer, et al.
Nature Immunology, 2012
- Endothelial Protein C Receptor
- Cytomegalovirus Infections
- Cytomegalovirus
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
156 found
Half-life
7.8 hr
Mechanism
Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade.
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.50 hr
Tmax = 0.50 hr
Half-life
7.8 hr
Terminal half life = 9.9 hr
Volume of distribution
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
The Protein C pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli. A lack of protein C in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation.
Protein C is available in concentrated form as the product Ceprotin, which is indicated for use in pediatric and adult patients with severe congenital protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
[L12831]
It is also found as a component of some prothrombin complex concentrate (i.e. [Factor IX Complex (Human)]) formulations, such as Kcentra.
[L12834]
Along with other blood coagulation factors, it is used to reverse acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with a need for an urgent surgery/invasive procedure.
[L50517]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 637 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Tmax = 0.50 hr
Terminal half life = 9.9 hr
Proteins and enzymes this drug interacts with in the body
ATC B01AD12
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Additional database identifiers
Drugs Product Database (DPD)
20131
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3542
GenAtlas
F5
GeneCards
F5
GenBank Gene Database
M16967
GenBank Protein Database
182412
UniProt Accession
FA5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3546
GenAtlas
F8
GeneCards
F8
GenBank Gene Database
M14113
GenBank Protein Database
182818
UniProt Accession
FA8_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q28852357), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.